| Literature DB >> 30078024 |
Tareq Al-Ayed1, Naveed Ur Rahman, Abdullah Alturki, Fahad Aljofan.
Abstract
BACKGROUND: Continuous renal replacement therapy (CRRT) has become the preferred mode of dialysis to support critically ill children with acute kidney injury. However, there are limited pediatric data on CRRT use, especially in our region.Entities:
Mesh:
Year: 2018 PMID: 30078024 PMCID: PMC6086670 DOI: 10.5144/0256-4947.2018.260
Source DB: PubMed Journal: Ann Saudi Med ISSN: 0256-4947 Impact factor: 1.526
Figure 1Gender distribution by age categories.
Characteristics of patients who underwent continuous renal replacement therapy (n=96).
| Characteristic | n (%) or mean (SD) |
|---|---|
|
| |
| 6.0 (4.4) | |
| <1 year | 23 (24) |
| 1–10 years | 56 (58.3) |
| >10 years | 17 (17.7) |
| Male | 54 (56.2) |
| Female | 42 (43.8) |
| Weight (kg) | 19.7 (12.9) |
| Height (cm) | 105.2 (32.4) |
| ICU LOS (days) | 14.9 (18.4) |
| 48 (50) | |
| Epinephrine | 44 (45.8) |
| Norepinephrine | 42 (43.8) |
| Dopamine | 30 (31.3) |
| Dobutamine | 10 (10.4) |
| Milrinone | 1 (1) |
| 66 (34.6–164.2) | |
| 30.9 (16.4–45.0) | |
| 30 (31.3) | |
| 43 (44.8) | |
| Fluid overload | 65 (67.2) |
| Tumor lysis syndrome | 18 (18.8) |
| Metabolic encephalopathy | 9 (9.4) |
| Increase oxalate | 4 (4.2) |
| Internal jugular | 74 (77.1) |
| Femoral | 18 (18.8) |
| Subclavian | 4 (4.2) |
| CVVHDF | 79 (82.3) |
| CVVHD | 9 (9.4) |
| CVVH | 6 (6.3) |
| SCUF | 2 (2.1) |
| 23 (24) | |
| RIFLE criteria | |
| Risk | 10 (10.4) |
| Injury | 19 (19.8) |
| Failure | 53 (55.2) |
| Loss | 0 (0) |
| ESRD | 14 (14.6) |
| Urine output (mL/kg/hr), median (IQR) | 0.8 (0.4–2.4) |
| GFR (mL/min/1.73m2), median (IQR) | 38.05 (20.5–66.1) |
| Discharged | 48 (50) |
| Died | 48 (50) |
Values are n (%) or mean (standard deviation) unless otherwise indicated. ICU LOS: intensive care unit length of stay; CRRT: continuous renal replacement therapy; SCUF: slow continuous ultrafiltration; CVVH: continuous veno-venous hemofiltration; CVVHD: continuous veno-venous hemodialysis; CVVHDF: continuous veno-venous hemodiafiltration; ESRD: end-stage renal disease; GFR: glomerular filtration rate (Schwartz Formula).
Primary diagnosis of critically ill pediatric patients undergone CRRT (N=96).
| Diagnosis | n (%) or mean (SD) |
|---|---|
|
| |
| Malignancies | 36 (37.5) |
| T cell acute lymphoblasticleukemia | 9 |
| Acute myelogenous leukemia | 7 |
| B cell acute lymphoblastic leukemia | 3 |
| Burkitt’s lymphoma | 8 |
| Hodgkin’s lymphoma | 2 |
| T cell lymphoma | 1 |
| Diffuse large B cell lymphoma | 1 |
| Neuroblastoma | 2 |
| Ewing sarcoma | 1 |
| Wilms tumor | 1 |
| Medulloblastoma | 1 |
| Hemolytic uremic syndrome | 5 |
| Nephrotic syndrome | 5 |
| Hyperoxaluria | 4 |
| Obstructive uropathy | 2 |
| Cystinosis | 1 |
| Polycystic kidney disease | 1 |
| Dysplastic kidneys | 1 |
| Severe combined immunodeficiency | 5 |
| Bare lymphocyte syndrome | 4 |
| Omenn syndrome | 3 |
| Chronic granulomatous disease | 1 |
| Hyper IgE syndrome | 1 |
| X-linked lymphoproliferative disease | 1 |
| Gracile syndrome | 1 |
| Maple syrup urine disease | 10 |
| Wilson disease | 3 |
| Propionic acidemia | 1 |
| Metachromatic leukodystrophy | 1 |
| Hemophagocytic lymphohistiocytosis | 5 |
| Myelodysplastic syndrome | 1 |
| Aplastic anemia | 3 |
| B thalassemia major | 1 |
Figure 2Outcome among patients who had undergone a stem cell transplant (n=30).
Figure 3Outcome by diagnosis and presence of septic shock (n=96).
Univariate analysis for increased mortality among patients undergoing continuous renal replacement therapy.
| Characteristics | Alive at discharge | Dead at discharge | OR | |
|---|---|---|---|---|
|
| ||||
| 6.3 (4.5) | 5.6 (4.2) | .467 | 0.653 (−1.122–2.430) | |
| <1 year | 10 (20.8) | 13 (27.1) | .169 | - |
| 1–10 years | 26 (54.2) | 30 (62.5) | ||
| >10 years | 12 (25) | 5 (10.4) | ||
| Male | 31 (64.6) | 23 (47.9) | .149 | 1.892 (0.874–4.495) |
| Female | 17 (35.4) | 25 (52.1) | ||
| 20.43 (13.5) | 18.92 (12.5) | .569 | 1.515 (−3.753–6.783) | |
| 107.4 (31.2) | 103.1 (33.7) | .516 | 4.327 (−8.836–17.491) | |
| 9.0 (5.6–14.6) | 11.7 (5.8–17.5) | .500 | - | |
| 7 (14.6) | 41 (85.4) | <.001 | 0.029 (0.009–0.021) | |
| Epinephrine | 6 (12.5) | 38 (79.2) | <.001 | 0.038 (0.012–0.113) |
| Norepinephrine | 4 (8.3) | 38 (79.2) | <.001 | 0.024 (0.007–0.083) |
| Dopamine | 2 (4.2) | 28 (58.3) | <.001 | 0.031 (0.007–0.143) |
| Dobutamine | 1 (2.1) | 9 (18.8) | .015 | 0.092 (0.011–0.760) |
| Milrinone | 0 (0) | 1 (2.1) | - | - |
| 61.3 (32.3–121.6) | 98.6 (39.3–206.8) | .051 | - | |
| 25 (14.1–44.6) | 35.29 (20.25–45) | .280 | - | |
| Fluid overload | 21 (43.8) | 44 (91.7) | <.001 | - |
| Metabolic encephalopathy | 7 (14.6) | 2 (4.2) | ||
| Tumor lysis syndrome | 16 (33.3) | 2 (4.2) | ||
| Increase oxalate | 4 (4.2) | 0 (0) | ||
| Femoral | 10 (20.8) | 8 (16.7) | .921 | - |
| Internal jugular | 36 (75) | 38 (79.2) | ||
| Subclavian | 2 (4.2) | 2 (4.2) | ||
| SCUF | 2 (4.2) | 0 (0) | .516 | - |
| CVVH | 4 (8.3) | 2 (4.2) | ||
| CVVHD | 4 (8.3) | 5 (10.4) | ||
| CVVHDF | 38 (79.2) | 41 (85.4) | ||
| 15 (31.2) | 8 (16.7) | .150 | 2.273 (0.858–6.020) | |
| RIFLE criteria | ||||
| Risk | 9 (18.8) | 1 (2.1) | <.001 | - |
| Injury | 15 (31.2) | 4 (8.3) | ||
| Failure | 13 (27.1) | 40 (83.3) | ||
| Loss | 0 (0) | 0 (0) | ||
| ESRD | 11 (22.9) | 3 (6.2) | ||
| 1.5 (0.4–3.9) | 0.6 (0.32–1.2) | .035 | - | |
| 32.8 (15.4–78.8) | 38.25 (25.7–55.4) | .631 | - | |
Values are n (%) or mean (standard deviation) unless otherwise indicated. ICU LOS: intensive care unit length of stay; CRRT: continuous renal replacement therapy; SCUF: slow continuous ultrafiltration; CVVH: continuous venovenous hemofiltration; CVVHD: continuous venovenous hemodialysis; CVVHDF: continuous venovenous hemodiafiltration; ESRD: end-stage renal disease; GFR: glomerular filtration rate (Schwartz Formula).
Multivariate logistic regression analysis for decreased survival among patients undergoing continuous renal replacement therapy (n=96).
| B | S.E. | Wald | df | Sig. | Exp (B) | 95% C.I. for Exp (B) | ||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
|
| ||||||||
| Sepsis with septic shock | −2.414 | 1.211 | 3.977 | 1 | .046 | .089 | .008 | .959 |
| Bone marrow transplant | .604 | 1.244 | .235 | 1 | .628 | 1.829 | .160 | 20.951 |
| Urine output before CRRT | −.081 | .282 | .082 | 1 | .775 | .922 | .531 | 1.603 |
| Inotropic support use | −2.603 | .763 | 11.643 | 1 | .001 | .074 | .017 | .330 |
| RIFLE criteria | −.148 | .406 | .134 | 1 | .714 | .862 | .389 | 1.909 |
| Length of CRRT | .004 | .003 | 1.291 | 1 | .256 | 1.004 | .997 | 1.010 |
| Constant | 6.836 | 1.937 | 12.451 | 1 | .000 | 931.030 | ||
Omnibus Tests of Model Coefficients: chi-square 66.845, df=6, P<.001; −2 Log likelihood 66.239; Cox & Snell R Square .502